Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12325150 | 0.86 | ABCB11 (0.51) | AURKAAURKBCDK2SYKJAK2 | |
| SCHEMBL3304918 | 0.81 | GSK3B (0.49) | AURKAAURKBCDK2SYKMAPK1 | |
| SCHEMBL14650748 | 0.80 | GRM4 (0.53) | GRM4AURKAAURKBCDK2CDK4 | |
| SCHEMBL4621510 | 0.79 | MAPK1 (0.61) | GRM4SYKMAPK1MEN1NPC1 | |
| SCHEMBL13440365 | 0.78 | AURKA (0.67) | AURKAAURKBCDK2CDK4CCNE1 | |
| SCHEMBL9277964 | 0.78 | BTK (0.59) | AURKAAURKBCDK2CDK4CCNE1 | |
| SCHEMBL12335153 | 0.78 | GRM4 (0.48) | GRM4AURKAAURKBCDK2CDK4 | |
| SCHEMBL1172227 | 0.76 | EPHB4 (0.62) | AURKAAURKBCDK2SYKJAK3 | |
| SCHEMBL14650531 | 0.76 | BTK (0.48) | GRM4AURKAAURKBCDK2CDK4 | |
| SCHEMBL12325148 | 0.75 | MAPK1 (0.41) | AURKAAURKBCDK2CDK4CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552214-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| WO-2011120026-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011120026-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | GRM4 4019/4885AURKA 70/4885AURKB 123/4885 |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | CDK2, MAP3K19, MAP3K1 | GRM4 3206/4885AURKA 70/4885AURKB 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.